Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to see how well quizartinib works to treat acute myeloid leukemia (AML). The people in this study have AML that does not have a genetic change called FLT3-ITD. In addition, they have not yet had any treatment for AML.
The purpose of this study is to assess the safety and effectiveness of the investigational drug ZEN003694 in people with advanced squamous cell lung cancer that continues to grow despite treatment and contains multiple copies of a gene called NSD3. ZEN003694 blocks a group of proteins called BET, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of lung cancer. ZEN003694 is taken orally (by mouth).
Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene.
The purpose of this study is to assess the safety and effectiveness of treating rare advanced genitourinary cancers with the immunotherapies nivolumab and ipilimumab plus the drug cabozantinib.
Researchers want to find the best dose of INCB161734 to use in people with advanced cancer. The people in this study have solid tumors that have spread. In addition, their cancers have a genetic mutation (change) called KRAS G12D.
In this study, researchers want to find the highest dose of the investigational drug ORIC-944 that can be given safely in people with metastatic prostate cancer that continues to grow despite standard treatments. ORIC-944 works by blocking a group of proteins called PRC2, which promote prostate cancer growth. It is taken orally (by mouth).
Researchers want to find the best dose of CBX-250 to treat leukemia that came back or keeps growing after treatment. The people in this study have one of these diseases:
The purpose of this study is to establish a registry of patients with a rare disease called pediatric-onset opsoclonus myoclonus ataxia syndrome (POOMAS). POOMAS affects the brain, spinal cord, and other nerves. Its exact cause is unknown, though a small number of patients with neuroblastoma may have this condition.
People with cancer often complain that their "mind does not seem to be clear." This can be due to stress, depression or anxiety, or physical problems, or may be due to some cancer treatments. The purpose of this study is to better understand the effects of cancer treatments on thinking (cognitive) abilities and memory in people with breast cancer over age 60. Thinking abilities and memory may decrease with age, and the effects of some treatments could make this problem worse in older people with breast cancer.
Idecabtagene vicleucel is a form of CAR T immunotherapy for multiple myeloma. People who have this treatment are usually monitored (watched) afterward, with no additional myeloma medications. In this study, researchers want to see if giving iberdomide as maintenance therapy after idecabtagene vicleucel is better than monitoring.
